XML 42 R56.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation - Narrative (Details) (USD $)
 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Jul. 31, 2012
Dec. 31, 2010
Dec. 31, 2012
Vertro
Mar. 01, 2012
Vertro
Feb. 29, 2012
Employee Compensation Plan 2010
Jan. 31, 2012
Employee Compensation Plan 2010
Dec. 31, 2011
Employee Compensation Plan 2010
Dec. 31, 2012
Employee Compensation Plan 2010
Dec. 31, 2011
2005 LTIP
Dec. 31, 2012
2005 LTIP
Sep. 30, 2011
Stock Options
Dec. 31, 2011
Stock Options
Jul. 31, 2012
Restricted Stock
Dec. 31, 2012
Restricted Stock
Dec. 31, 2011
Restricted Stock
Jul. 31, 2012
Restricted Stock
Executive Officers, Senior Management and Board of Directors
Jul. 31, 2012
Restricted Stock
Management
Jul. 31, 2012
Restricted Stock
Non-management
Dec. 31, 2012
RSA
Dec. 31, 2011
RSA
Dec. 31, 2011
RSA
Executive Officers and Senior Management
Dec. 31, 2011
RSA
Board of Directors
Dec. 31, 2012
RSA
Board of Directors
Dec. 31, 2012
Minimum
Dec. 31, 2011
Minimum
RSA
Dec. 31, 2012
Maximum
Dec. 31, 2011
Maximum
RSA
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                                          
Option and restricted stock unit vesting period                                                   0 years   3 years  
Award extension of expiration term                         5 years                                
Award extension period, expected life                         1 year                                
Increase (decrease) in fair value                         $ 283,000                                
Stock-based compensation expense 843,000 957,000                       117,000             15,000 573,000              
Compensation cost related to non vested awards not yet recognized 444,000                         166,000                              
Number of additional shares authorized (in shares)             2,500,000 100,357                                          
Number of shares authorized (in shares) 4,385,945                 3,385,945   1,000,000                                  
Equity instruments other than options, grants in period (in shares)                             445,500 1,271,008   296,505 148,995 49,500   326,291              
Equity instruments other than options, nonvested, weighted average grant date fair value (usd per share)     $ 0.56                         $ 0.70 $ 1.73                        
Expected forfeiture rate 25.00%                                                        
Number of options granted (in shares) 49,500 340,000             300,000   40,000                                    
Weighted average exercise price granted (usd per share) $ 0.56 $ 2.83             $ 2.93   $ 2.05                                    
Aggregate intrinsic value of outstanding options 0       0                                                
Weighted average remaining contractual term 7 years 1 month 6 days       2 years 1 month 27 days                                                
Number of options exercisable (in shares) 896,101 629,043                                                      
Aggregate intrinsic value of exercisable options outstanding 0                                                        
Weighted average exercise price exercisable (usd per share) $ 2.79 $ 3.03                                                      
Weighted average remaining contractual term exercisable options 6 years 10 months 24 days                                                        
Average remaining expense recognition period 7 months 16 days                                                        
Options, vested in period, total fair value 609,000 466,000                                                      
Options, vested in period, total fair value, per share $ 2.28                                                        
Option granted, weighted average grant date fair value $ 0.49 $ 2.83                                                      
Number of options outstanding (in shares) 1,179,199 1,358,717   1,223,159 110,822 118,842       605,590   573,509                                  
Number of options expired (in shares) 229,018 204,442     8,020                                                
Weighted average exercise price expired options (usd per share) $ 3.09 $ 6.61     $ 32.15                                                
Options, weighted average exercise price (usd per share) $ 2.66 $ 2.81   $ 3.74 $ 69.00                                                
Options, weighted average fair value         0                                                
Deferred compensation                                             418,000 72,000          
Aggregate intrinsic value                                                 $ 36,000        
Weighted average grant date fair value (usd per share)                               $ 0.78                     $ 1.09   $ 2.94